Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PS beta-9 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PSMB9 (PS beta-9) Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PSMB9 Products |
| Gene Delivery | PSMB9 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PSMB9 Products |
| Benchmark Ab | Anti-PSMB9 (LMP2) Recombinant Antibody Recombinant positive control for assay validation. |
View PSMB9 Products |
| Validator | PSMB9 siRNA Set For knockdown verification in target engagement assays. |
View PSMB9 Products |
| Related Target A | PSMB8 (LMP7) Synergistic immunoproteasome subunit; key for dual-inhibition strategy. |
View PSMB8 Products |
| Related Target B | PSMB6 (beta-1) Constitutive counterpart; essential for off-target counter-screening. |
View PSMB6 Products |
| Related Target C | PSMB10 (MECL-1) Essential component of the immunoproteasome complex. |
View PSMB10 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity counter-screening against constitutive proteasome | Homolog panel proteins (PSMB5, PSMB6) strictly verified by mass spec. High-purity PSMB9 and PSMB6 recombinant proteins available. |
| Assaying active site conformation under native conditions | HEK293 expressed proteins preserving native-like post-translational modifications. |
| Lack of positive control reagents | Clinical-grade recombinant benchmark antibodies available. |
| False positive small-molecule screening readouts | Validated sequence-specific siRNA included for genetic knockdown validation. |
Live PS beta-9 (PSMB9) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PS beta-9 (PSMB9) therapeutics is intensifying, with major players shifting focus from broad pan-proteasome inhibitors to highly selective immunoproteasome subunit modulators. As first-generation therapies reach the clinic, the next wave of R&D is targeting selective small molecule inhibitors for autoimmune diseases (such as Lupus Nephritis and Rheumatoid Arthritis) and relapsed/refractory multiple myeloma, aiming to minimize the toxicity associated with constitutive proteasome inhibition. Dual PSMB8/PSMB9 inhibition and small-molecule degraders (PROTACs) are being explored to overcome acquired drug resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Kezar Life Sciences, Principia Biopharma, Onyx Pharmaceuticals | Lupus Nephritis, Rheumatoid Arthritis, Multiple Myeloma | Selectivity Profiling (Need high-purity PSMB9 vs PSMB6/PSMB5 proteins) |
| PROTACs / Degraders | Arvinas, Emerging Biotechs | Multiple Myeloma, Autoimmune Diseases, Refractory Cancers | Target Degradation Assay (Need PSMB9 Lentivirus for stable cell lines and specific antibodies) |
| Monoclonal Antibodies | Academic Research Institutes | Diagnostic Pathology, Biomarker Profiling | High-specificity binding validation (Need Sequence-verified PSMB9 Antigen) |
| Peptide Therapeutics | Academic Spin-offs | Inflammatory Bowel Disease | Binding Affinity (Need Sequence Verified recombinant proteins) |